|
|
|
| Visual analysis of knowledge map correlation between cirrhosis and gut microbiota |
| YAO Yiqi1 YANG Yaxin2 CHEN Xuanrui1 CHEN Daman3 HOU Zhengkun4 |
1.The First Medicine College of Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510405, China;
2.the Second Medicine College of Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510405, China;
3.the Fourth Medicine College of Guangzhou University of Chinese Medicine, Guangdong Province, Shenzhen 518033, China;
4.Department of Gastroenterology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510405, China
|
|
|
|
Abstract Objective To analyze the relationship of cirrhosis and gut microbiota by text network analysis. Methods By using VOSviewer and CiteSpace, the author and institutional cooperation network, keywords and breakout words of the literatures collected by CNKI and WOS from January 1992 to June 2022 were analyzed. Results A total of 1 000 articles were included. The Chinese author had five cooperative groups, and the English author was mainly Jasmohan S Bajaj team. Research institutions were concentrated in universities and affiliated hospitals; the high-frequency keywords were probiotics, endotoxins, etc., and the research focused on intestinal bacterial translocation and microecological preparations. Conclusion The knowledge map shows the research progress of liver cirrhosis and intestinal flora, focusing on the relationship between microbial preparations, microbial metabolites and liver cirrhosis. Future hotspots may be related to preventing gut microbiota imbalance and exploring the mechanism of bacterial flora transplantation.
|
|
|
|
|
|
[1] Sekirov I，Russell SL，Antunes L，et al. Gut microbiota in health and disease [J]. Physiological Reviews，2010，90（3）：859-904.
[2] 刘玉，张宇一，邹颖，等.肠道微生态与自发性细菌性腹膜炎的关系[J].临床肝胆病杂志，2021，37（2）：425-428.
[3] Usami M，Miyoshi M，Yamashita H. Gut microbiota and host metabolism in liver cirrhosis [J]. World J Gastroenterol，2015， 21（41）：11597-11608.
[4] 陈悦，陈超美，刘则渊，等.CiteSpace知识图谱的方法论功能[J].科学学研究，2015，33（2）：242-253.
[5] 高凯.文献计量分析软件VOSviewer的应用研究[J].科技情报开发与经济，2015（12）：95-98.
[6] 中华预防医学会微生态学分会.中国微生态调节剂临床应用专家共识（2020版）[J].中华临床感染病杂志，2020， 13（4）：241-256.
[7] 王明亮，丁永芳，印鑫，等.基于肠-肝-肾轴的肝纤维化与肾纤维化研究进展[J].药学学报，2021，56（1）：9-20.
[8] 皮宇，高侃，朱伟云.动物宿主—肠道微生物代谢轴研究进展[J].微生物学报，2017，57（2）：161-169.
[9] 冯锦凯，陈振华，武宇轩，等.肠道菌群在慢性肝病和肝细胞癌中的作用及临床意义[J].第二军医大学学报，2020，41（11）：1246-1249.
[10] 张群，王宪波.肠道菌群在门静脉高压发病机制中的作用[J].临床肝胆病杂志，2020，36（3）：673-676.
[11] 高明月，杨雅坤，殷雅楠，等.肠道菌群介导的非酒精性脂肪性肝病发病机制研究进展[J].解放军医学杂志，2020，45（9）：990-995.
[12] 陈默，刀永祥.肠道菌群与原发性肝癌相关性的研究进展[J].中国肿瘤临床，2020，47（18）：961-964.
[13] 于兴华，马晓莹，张鹏，等.酪酸梭菌与胃肠道及肝脏疾病的研究进展[J].中国微生态学杂志，2020，32（4）：472- 476，封3.
[14] Stadlbauer V，Komarova I，Klymiuk I，et al. Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis [J]. Liver Int，2020，40（4）：866-877.
[15] 刘林祥，聂源，朱萱.质子泵抑制剂与肝硬化并发症的研究进展[J].临床肝胆病杂志，2020，36（11）：2557-2560.
[16] Hassouneh R，Bajaj JS. Gut Microbiota Modulation and Fecal Transplantation：An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment [J]. J Clin Med，2021， 10（2）：330.
[17] Keshavarz S，Ashrafian F，Yadegar A，et al. The Protective Effects of Live and Pasteurized Akkermansia muciniphila and Its Extracellular Vesicles against HFD/CCl4-Induced Liver Injury [J]. Microbiol Spectr，2021，9（2）：e0048421.
[18] Zhang Y，Zhao M，Jiang X，et al. Comprehensive Analysis of Fecal Microbiome and Metabolomics in Hepatic Fibrosis Rats Reveal Hepatoprotective Effects of Yinchen Wuling Powder From the Host-Microbial Metabolic Axis [J]. Front Pharmacol，2021，12：713197.
[19] D’Onofrio F，Renga G，Puccetti M，et al. Indole-3-Car- boxaldehyde Restores Gut Mucosal Integrity and Protects from Liver Fibrosis in Murine Sclerosing Cholangitis [J]. Cells，2021，10（7）：1622.
[20] Wang C，Ma C，Fu K，et al. Phillygenin Attenuates Carbon Tetrachloride-Induced Liver Fibrosis via Modulating In- flammation and Gut Microbiota [J]. Front Pharmacol，2021， 12：756924.
[21] Huan H，Ren T，Xu L，et al. Compositional distinction of gut microbiota between Han Chinese and Tibetan populations with liver cirrhosis [J]. Peer J，2021，9：e12142.
[22] 郭晓霞，胡娜，廉晓晓，等.肝硬化患者肠道菌群失调的特征及驱动因子分析[J].临床肝胆病杂志，2020，36（7）： 1527-1533.
[23] 李强，朱清亮，张海龙，等.肝硬化患者经颈静脉肝内门体分流术前后肠道菌群特征分析[J].临床肝胆病杂志，2020，36（2）：333-337.
[24] 栾雨婷，蔡文君，蒋轼丽，等.乙型肝炎肝硬化患者伴或不伴腹水对肠道菌群的影响[J].临床肝胆病杂志，2020， 36（7）：1520-1526.
[25] Patel C，Lee S，Mcphail W，et al. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cir- rhosis and encephalopathy：RIFSYS randomised controlled trial [J]. J Hepatol，2022，76（2）：332-342. |
|
|
|
